nodes	percent_of_prediction	percent_of_DWPC	metapath
Clenbuterol—TNF—Graves' disease	0.84	1	CbGaD
Clenbuterol—CYP1A2—Methimazole—Graves' disease	0.0987	1	CbGbCtD
Clenbuterol—NGF—eye—Graves' disease	0.00367	0.285	CbGeAlD
Clenbuterol—NGF—thyroid gland—Graves' disease	0.00235	0.182	CbGeAlD
Clenbuterol—ADRB3—connective tissue—Graves' disease	0.00225	0.175	CbGeAlD
Clenbuterol—ADRB3—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.00185	0.0379	CbGpPWpGaD
Clenbuterol—ADRB3—adipose tissue—Graves' disease	0.00173	0.134	CbGeAlD
Clenbuterol—TNF—Death Receptor Signalling—FASLG—Graves' disease	0.00147	0.03	CbGpPWpGaD
Clenbuterol—TNF—Death Receptor Signalling—FAS—Graves' disease	0.00142	0.0289	CbGpPWpGaD
Clenbuterol—NGF—SHP2 signaling—IL2RA—Graves' disease	0.00124	0.0253	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—TNFRSF25—Graves' disease	0.00118	0.0242	CbGpPWpGaD
Clenbuterol—ADRB2—Arf6 signaling events—TSHR—Graves' disease	0.00113	0.0231	CbGpPWpGaD
Clenbuterol—ADRB1—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.0011	0.0225	CbGpPWpGaD
Clenbuterol—ADRB2—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.00108	0.022	CbGpPWpGaD
Clenbuterol—ADRB1—connective tissue—Graves' disease	0.000921	0.0715	CbGeAlD
Clenbuterol—ADRB2—Arf6 trafficking events—TSHR—Graves' disease	0.000892	0.0182	CbGpPWpGaD
Clenbuterol—NGF—SHP2 signaling—IFNG—Graves' disease	0.000818	0.0167	CbGpPWpGaD
Clenbuterol—TNF—Cytokines and Inflammatory Response—HLA-DRB1—Graves' disease	0.000752	0.0154	CbGpPWpGaD
Clenbuterol—TNF—HIV-1 Nef: Negative effector of Fas and TNF-alpha—FASLG—Graves' disease	0.000739	0.0151	CbGpPWpGaD
Clenbuterol—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—Graves' disease	0.000734	0.015	CbGpPWpGaD
Clenbuterol—TNF—HIV-1 Nef: Negative effector of Fas and TNF-alpha—FAS—Graves' disease	0.000713	0.0146	CbGpPWpGaD
Clenbuterol—ADRB3—G alpha (s) signalling events—TSHR—Graves' disease	0.000707	0.0145	CbGpPWpGaD
Clenbuterol—ADRB1—adipose tissue—Graves' disease	0.000706	0.0549	CbGeAlD
Clenbuterol—TNF—amb2 Integrin signaling—ICAM1—Graves' disease	0.00063	0.0129	CbGpPWpGaD
Clenbuterol—TNF—FAS pathway and Stress induction of HSP regulation—FASLG—Graves' disease	0.00061	0.0125	CbGpPWpGaD
Clenbuterol—TNF—FAS pathway and Stress induction of HSP regulation—FAS—Graves' disease	0.000588	0.012	CbGpPWpGaD
Clenbuterol—TNF—Cellular roles of Anthrax toxin—IL1B—Graves' disease	0.000577	0.0118	CbGpPWpGaD
Clenbuterol—TNF—IL27-mediated signaling events—IFNG—Graves' disease	0.000566	0.0116	CbGpPWpGaD
Clenbuterol—NGF—MAPK Signaling Pathway—FASLG—Graves' disease	0.000552	0.0113	CbGpPWpGaD
Clenbuterol—TNF—Cytokines and Inflammatory Response—IFNG—Graves' disease	0.000549	0.0112	CbGpPWpGaD
Clenbuterol—NGF—MAPK Signaling Pathway—FAS—Graves' disease	0.000533	0.0109	CbGpPWpGaD
Clenbuterol—TNF—Cytokines and Inflammatory Response—CD4—Graves' disease	0.00053	0.0108	CbGpPWpGaD
Clenbuterol—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—Graves' disease	0.00053	0.0108	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—HLA-E—Graves' disease	0.000528	0.0108	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—CD40—Graves' disease	0.000516	0.0106	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—CTLA4—Graves' disease	0.000509	0.0104	CbGpPWpGaD
Clenbuterol—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—Graves' disease	0.000508	0.0104	CbGpPWpGaD
Clenbuterol—TNF—IL27-mediated signaling events—IL1B—Graves' disease	0.000505	0.0103	CbGpPWpGaD
Clenbuterol—TNF—Cytokines and Inflammatory Response—IL1B—Graves' disease	0.00049	0.01	CbGpPWpGaD
Clenbuterol—TNF—Caspase Cascade in Apoptosis—FASLG—Graves' disease	0.000478	0.00976	CbGpPWpGaD
Clenbuterol—TNF—Caspase Cascade in Apoptosis—FAS—Graves' disease	0.00046	0.00941	CbGpPWpGaD
Clenbuterol—CYP1A1—adipose tissue—Graves' disease	0.000456	0.0354	CbGeAlD
Clenbuterol—TNF—Downstream signaling in naïve CD8+ T cells—CD8A—Graves' disease	0.000452	0.00923	CbGpPWpGaD
Clenbuterol—TNF—Vitamin B12 Metabolism—ICAM1—Graves' disease	0.000434	0.00887	CbGpPWpGaD
Clenbuterol—TNF—Monoamine Transport—IL1B—Graves' disease	0.000428	0.00874	CbGpPWpGaD
Clenbuterol—TNF—IL23-mediated signaling events—IFNG—Graves' disease	0.000427	0.00873	CbGpPWpGaD
Clenbuterol—TNF—Downstream signaling in naïve CD8+ T cells—FASLG—Graves' disease	0.000425	0.00868	CbGpPWpGaD
Clenbuterol—TNF—Toll-like Receptor Signaling Pathway—CD40—Graves' disease	0.000421	0.0086	CbGpPWpGaD
Clenbuterol—ADRB1—G alpha (s) signalling events—TSHR—Graves' disease	0.00042	0.00858	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—HLA-DQB1—Graves' disease	0.000419	0.00856	CbGpPWpGaD
Clenbuterol—TNF—IL23-mediated signaling events—CD4—Graves' disease	0.000412	0.00843	CbGpPWpGaD
Clenbuterol—ADRB2—G alpha (s) signalling events—TSHR—Graves' disease	0.000411	0.00839	CbGpPWpGaD
Clenbuterol—TNF—Downstream signaling in naïve CD8+ T cells—IL2RA—Graves' disease	0.000407	0.00832	CbGpPWpGaD
Clenbuterol—TNF—Downstream signaling in naïve CD8+ T cells—HLA-A—Graves' disease	0.000403	0.00823	CbGpPWpGaD
Clenbuterol—CYP1A2—thyroid gland—Graves' disease	0.0004	0.0311	CbGeAlD
Clenbuterol—CYP1A1—thyroid gland—Graves' disease	0.000394	0.0306	CbGeAlD
Clenbuterol—TNF—IL23-mediated signaling events—IL1B—Graves' disease	0.000381	0.00778	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—HLA-B—Graves' disease	0.000376	0.00769	CbGpPWpGaD
Clenbuterol—TNF—Toll-like Receptor Signaling Pathway—CXCL10—Graves' disease	0.000376	0.00769	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—FASLG—Graves' disease	0.000368	0.00752	CbGpPWpGaD
Clenbuterol—TNF—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	0.000359	0.00733	CbGpPWpGaD
Clenbuterol—TNF—Alzheimers Disease—FAS—Graves' disease	0.000355	0.00725	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—FAS—Graves' disease	0.000355	0.00725	CbGpPWpGaD
Clenbuterol—TNF—Folate Metabolism—ICAM1—Graves' disease	0.000353	0.00722	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—IL2RA—Graves' disease	0.000353	0.00721	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—FASLG—Graves' disease	0.00035	0.00716	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—HLA-A—Graves' disease	0.000349	0.00713	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—FAS—Graves' disease	0.000338	0.0069	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000337	0.00689	CbGpPWpGaD
Clenbuterol—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—Graves' disease	0.000335	0.00686	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—CXCL10—Graves' disease	0.000335	0.00684	CbGpPWpGaD
Clenbuterol—NGF—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.000331	0.00676	CbGpPWpGaD
Clenbuterol—TNF—Vitamin B12 Metabolism—IFNG—Graves' disease	0.00033	0.00675	CbGpPWpGaD
Clenbuterol—TNF—Regulation of toll-like receptor signaling pathway—CD40—Graves' disease	0.000328	0.00671	CbGpPWpGaD
Clenbuterol—TNF—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	0.00032	0.00654	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—HLA-DRB1—Graves' disease	0.000319	0.00651	CbGpPWpGaD
Clenbuterol—TNF—TGF-beta Receptor Signaling—IFNG—Graves' disease	0.000315	0.00645	CbGpPWpGaD
Clenbuterol—NGF—MAPK Signaling Pathway—IL1B—Graves' disease	0.000312	0.00637	CbGpPWpGaD
Clenbuterol—TNF—Vitamin B12 Metabolism—IL1B—Graves' disease	0.000294	0.00602	CbGpPWpGaD
Clenbuterol—TNF—Regulation of toll-like receptor signaling pathway—CXCL10—Graves' disease	0.000294	0.006	CbGpPWpGaD
Clenbuterol—TNF—Selenium Micronutrient Network—ICAM1—Graves' disease	0.00028	0.00573	CbGpPWpGaD
Clenbuterol—TNF—Downstream signaling in naïve CD8+ T cells—IFNG—Graves' disease	0.000269	0.00549	CbGpPWpGaD
Clenbuterol—TNF—Folate Metabolism—IFNG—Graves' disease	0.000269	0.00549	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—TSHR—Graves' disease	0.000257	0.00525	CbGpPWpGaD
Clenbuterol—NGF—SIDS Susceptibility Pathways—TNF—Graves' disease	0.00024	0.00491	CbGpPWpGaD
Clenbuterol—TNF—Folate Metabolism—IL1B—Graves' disease	0.00024	0.0049	CbGpPWpGaD
Clenbuterol—TNF—Adipogenesis—FAS—Graves' disease	0.000238	0.00487	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—IFNG—Graves' disease	0.000233	0.00476	CbGpPWpGaD
Clenbuterol—NGF—MAPK Signaling Pathway—TNF—Graves' disease	0.000226	0.00462	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—ICAM1—Graves' disease	0.000222	0.00453	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000218	0.00445	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—FASLG—Graves' disease	0.000215	0.00439	CbGpPWpGaD
Clenbuterol—TNF—Selenium Micronutrient Network—IFNG—Graves' disease	0.000213	0.00436	CbGpPWpGaD
Clenbuterol—TNF—Alzheimers Disease—IL1B—Graves' disease	0.000208	0.00424	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—IL1B—Graves' disease	0.000208	0.00424	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—FAS—Graves' disease	0.000207	0.00423	CbGpPWpGaD
Clenbuterol—TNF—MAPK Signaling Pathway—FASLG—Graves' disease	0.000201	0.00411	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.0002	0.00409	CbGpPWpGaD
Clenbuterol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	0.000197	0.00402	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000196	0.004	CbGpPWpGaD
Clenbuterol—TNF—MAPK Signaling Pathway—FAS—Graves' disease	0.000194	0.00396	CbGpPWpGaD
Clenbuterol—TNF—Selenium Micronutrient Network—IL1B—Graves' disease	0.00019	0.00389	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000182	0.00371	CbGpPWpGaD
Clenbuterol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	0.000176	0.00359	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000175	0.00358	CbGpPWpGaD
Clenbuterol—TNF—Toll-like Receptor Signaling Pathway—IL1B—Graves' disease	0.000169	0.00346	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—IFNG—Graves' disease	0.000169	0.00345	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—CXCL10—Graves' disease	0.000166	0.00339	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—TSHR—Graves' disease	0.000152	0.00312	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—IL1B—Graves' disease	0.000151	0.00308	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—TSHR—Graves' disease	0.00015	0.00308	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—TSHR—Graves' disease	0.000149	0.00305	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—TSHR—Graves' disease	0.000145	0.00297	CbGpPWpGaD
Clenbuterol—TNF—Regulation of toll-like receptor signaling pathway—IL1B—Graves' disease	0.000132	0.0027	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—TSHR—Graves' disease	0.000132	0.00269	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000129	0.00264	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000129	0.00263	CbGpPWpGaD
Clenbuterol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	0.000127	0.0026	CbGpPWpGaD
Clenbuterol—CYP1A1—Aryl Hydrocarbon Receptor—TNF—Graves' disease	0.000127	0.0026	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000127	0.00259	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	0.000125	0.00257	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.00012	0.00246	CbGpPWpGaD
Clenbuterol—TNF—MAPK Signaling Pathway—IL1B—Graves' disease	0.000113	0.00232	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	0.000112	0.00229	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—CXCL10—Graves' disease	9.85e-05	0.00201	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—CXCL10—Graves' disease	9.72e-05	0.00199	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—CXCL10—Graves' disease	9.63e-05	0.00197	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—CXCL10—Graves' disease	9.38e-05	0.00192	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—TSHR—Graves' disease	8.61e-05	0.00176	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—CXCL10—Graves' disease	8.52e-05	0.00174	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—TSHR—Graves' disease	8.43e-05	0.00172	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—GC—Graves' disease	8.2e-05	0.00168	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	8.12e-05	0.00166	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	8.12e-05	0.00166	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—TSHR—Graves' disease	7.82e-05	0.0016	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—TSHR—Graves' disease	7.78e-05	0.00159	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—TSHR—Graves' disease	7.65e-05	0.00156	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—IL2RA—Graves' disease	7.43e-05	0.00152	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—IL2RA—Graves' disease	7.17e-05	0.00147	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—IL2RA—Graves' disease	6.51e-05	0.00133	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—GC—Graves' disease	5.73e-05	0.00117	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—CXCL10—Graves' disease	5.57e-05	0.00114	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—CXCL10—Graves' disease	5.44e-05	0.00111	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—CXCL10—Graves' disease	5.05e-05	0.00103	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—CXCL10—Graves' disease	5.03e-05	0.00103	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—CXCL10—Graves' disease	4.94e-05	0.00101	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—TSHR—Graves' disease	4.62e-05	0.000945	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—TSHR—Graves' disease	4.52e-05	0.000924	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—B3GNT2—Graves' disease	4.34e-05	0.000887	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—IL2RA—Graves' disease	4.25e-05	0.00087	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—IL2RA—Graves' disease	4.16e-05	0.000851	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—IL2RA—Graves' disease	3.86e-05	0.00079	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—IL2RA—Graves' disease	3.84e-05	0.000786	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—IL2RA—Graves' disease	3.78e-05	0.000773	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—GC—Graves' disease	3.65e-05	0.000747	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—CXCL10—Graves' disease	2.99e-05	0.00061	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—CXCL10—Graves' disease	2.92e-05	0.000597	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—B3GNT2—Graves' disease	2.77e-05	0.000566	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—IL2RA—Graves' disease	2.28e-05	0.000467	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—IL2RA—Graves' disease	2.23e-05	0.000456	CbGpPWpGaD
